Clinical Trial Update: Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating mipomersen (ISIS 301012) and its effect on liver fat content in lipid metabolism disorders and hyperlipidemia; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hyperlipidemia
• Lipid Metabolism Disorders

Drugs mentioned

• Kynamro (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Lipid Metabolism, Inborn Errors, Hyperlipidemias | Phase 2 | Status: COMPLETED | Results posted: 2015-06-24